According to the World Health Organization, cancer is a leading cause of mortality and accounted for approximately 10 million deaths in 2020. Therefore, continued research regarding understanding, diagnosing, and treating cancer is a global priority. The ever-evolving field of oncology spans innovations and discoveries in tumor biology, immunotherapy, targeted treatments, early detection, and personalized medicine.

The mission of MDPI’s cluster of oncology-related journals is to publish high-impact research with potential to redefine cancer treatment and care. Addressing topics from solid tumors to hematologic malignancies, from rare cancers to novel therapeutics, these journals provide a dynamic platform for groundbreaking discoveries and clinical advancements that shape the future of oncology.

The six participating journals are as follows:

• Cancers (ISSN 2072-6694) focuses on publishing high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics. In particular, it showcases the most seminal studies in the rapidly growing areas of immunology, immunotherapy, and tumor microenvironment research. Cancers is led by its Editor-in-Chief, Prof. Dr. Samuel C. Mok;
• Current Oncology (ISSN 1718-7729) is dedicated to advancing cancer care and therapy via publishing clinically relevant research with direct applications to oncology practice. Since its establishment in 1994, the journal has played an important role in disseminating new knowledge across the entire cancer care continuum, spanning the prevention, early detection, and diagnosis of cancer; treatment, including systemic therapy, radiation therapy, and surgery; supportive care; and survivorship care. Additionally, it highlights the critical role of biomarkers and biomarker-driven research in guiding personalized oncology. Affiliated with several key cancer societies, Current Oncology provides a global platform to share scientific progress in oncology. The journal is led by its Editor-in-Chief, Prof. Dr. Shahid Ahmed;
• Onco (ISSN 2673-7523) functions as a scientific forum integrating novel preclinical, translational, and clinical cancer research and is focused on (but not limited to) the following topics: cancer cell signaling; cancer genetics and molecular targets; cancer epigenetics and heterogeneity; carcinogenesis and cancer evolution; microbiomes and cancer; cancer metabolomics; cancer biomarkers; cancer dormancy; novel targeted and immune cancer therapies; randomized clinical trials; oncotargets; cancer therapies; and clinical reports proposing novel therapeutic regimens. Onco is led by its Editor-in-Chief, Dr. Constantin N. Baxevanis;
• Targets (ISSN 2813-3137) is centered on, but not limited to, discovering novel molecules which act as diagnostic biomarkers and therapeutic targets, establishing new bionic recognition systems for biosensing and bioimaging, developing novel approaches for biomarker detection, related applications of biological interaction monitoring and targeted therapy, designing new signal amplification strategies for biosensing and cellular or in vivo imaging, utilizing molecular recognition for single-molecule or single-cell analysis, elucidating new pathways or mechanisms in disease development and progression, and synthesizing smart nanomaterials for activatable imaging and responsive drug release. Targets is led by its Editor-in-Chief, Prof. Dr. Huangxian Ju;
• Precision Oncology (ISSN 3042-7614) is an international, peer-reviewed, open access journal in the field of precision oncology. Our aim is to publish advances in personalized translational and clinical oncology research. We welcome empirical research articles, reviews, and commentaries that contribute to a deeper understanding of cancer diagnoses, prognoses, prevention, and treatment specifically for individual patients. Precision Oncology is led by its Editor-in-Chief, Prof. Dr. Raul A. Urrutia;
• Therapeutics (ISSN 2813-9909) is an international, peer-reviewed, open access journal on both modern and established traditional therapeutic techniques. Therapeutics aims to publish cutting-edge research focused on the prevention and treatment of human disease. Therapeutics publishes reviews, original research, guidelines, and communications. Therapeutics is led by its Editor-in-Chief, Prof. Dr. Nejat Düzgüneş.

	Launch Year	Impact Factor (2024)	CiteScore (2024)	Time to First Decision (Median)	APC (CHF)
	2009	4.4	8.8	19.1 days	2900
	1994	3.4	4.9	22.8 days	2200
	2021	/	/	23.7 days	1000
	2023	/	/	20.9 days	1000
	2026			19 days	1000
	2024			18 days	1000

MDPI’s mission and values:

As a pioneer in academic open access publishing, MDPI has been serving the scientific community since 1996. Our aim is to foster scientific exchange in all forms and across all disciplines. MDPI's guidelines for disseminating open science are based on the following values and guiding principles:

• Open Access—All our content is published in open access format and distributed under a Creative Commons License, providing free access to the latest research and allowing articles to be freely shared and content to be re-used with proper attribution;
• Timeliness and Efficiency—We rapidly publish novel research through a thorough editorial process, ensuring that a first decision is provided to authors in under 32 days and that papers are published within 7–10 days upon acceptance;
• Simplicity—We offer user-friendly tools and services on our integrated system to enhance the efficiency of our editorial process;
• High-Quality Service—We support scholars and their work by providing a range of options, such as publication in journals at mdpi.com, early publication at preprints.org, and the publication of conferences at sciforum.net, to positively impact research;
• Flexibility—We adapt and develop new tools and services to meet the changing needs of the research community, driven by feedback from authors, editors, and readers;
• Rooted in Sustainability—We ensure the long-term preservation of published papers and support the future of science through partnerships, sponsorships, and awards.

By adhering to these values and principles, MDPI remains committed to advancing scientific knowledge and promoting open-science practices.

Selected Topics:

• “Cancer Biology and Radiation Therapy: 2nd Edition”;
• “Hepatobiliary and Pancreatic Diseases: Novel Strategies of Diagnosis and Treatments”;
• “Biomarkers of Disease: Discovery and Clinical Applications”;
• “Recent Advances in Anticancer Strategies, 2nd Edition”.

Selected Articles:

Cancers
“Generation of Hydrogen Peroxide in Cancer Cells: Advancing Therapeutic Approaches for Cancer Treatment”
by Taufeeque Ali, Daniel Li, Thilini Nimasha Fernando Ponnamperumage, Alexis Kimberly Peterson, Jatin Pandey, Kulsum Fatima, John Brzezinski, Julia Anna Rose Jakusz, Hanlun Gao, Gilbert Edward Koelsch et al.
Cancers 2024, 16(12), 2171; https://doi.org/10.3390/cancers16122171

Current Oncology
“Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse”
by Parva Bhatt, Colin Kloock and Raymond Comenzo
Curr. Oncol. 2023, 30(2), 2322-2347; https://doi.org/10.3390/curroncol30020179

Onco
“Significance of PET/CT Imaging in Myeloma Assessment: Exploring Novel Applications beyond Osteolytic Lesion Detection and Treatment Response”
by Mahdi Zirakchian Zadeh
Onco 2024, 4(1), 15-36; https://doi.org/10.3390/onco4010002

Targets
“Potential of MMP-2 and MMP-9 Gelatinase Blockade as a Therapeutic Strategy in Fibrosarcoma Treatment: A Decadal Review”
by Alireza Shoari
Targets 2024, 2(2), 104-125; https://doi.org/10.3390/targets2020007

Precision Oncology
“Treatment of Resistant TPM3::ALK + Fusion Protein Metastatic Inflammatory Myofibroblastic Tumor with ALK Targeting and Immune Checkpoint Inhibitor Combined Therapy”
by Leonardo Simonelli, Sebastian James Khairkhahan, Francesco Alessandrino, Elizabeth Anne Montgomery and Gina D’Amato
Precis. Oncol. 2026, 1(1), 1; https://doi.org/10.3390/precisoncol1010001

Therapeutics
“How Natural Therapies Can Combat Neoplastic Disease by Targeting Key Survival Mechanisms and Signaling Pathways”
by Simge Karagil, Aleksandra Szczesnowska, Natalia Haddad, Sara Magura Gamaethige, Ellen Coakley, Nabila Dawood, Vernard J. Rama, James Barker, Moses K. Langat, Huda Morgan et al.
Therapeutics 2025, 2(1), 5; https://doi.org/10.3390/therapeutics2010005